IRCT2015061822805N1已完成1 期
The efficiency of recombinant human erythropoietin in reducing the need for blood transfusions in patients with solid tumors receiving chemotherapy.
Vice Chancellor for research of Tabriz University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 year 至 15 years（—）
- 性别
- All
入选标准
- •Age of the patients, entering the study, should be beneath 15 years; The amount of Hemoglobin should be below 10 g/dL(gram per deciliter); Patients who are anemic due to chemotherapy, after they are diagnosed with solid insitu tumor; None of the patients have bone marrow involvement; Patients entering the study have normal kidney,liver,and lung function; Normal amounts of other blood-related parameters including retic.count, Serum ferritin, B12 vitamin in the serum, direct and indirect coombs tests, and ABG(Arterial Blood Gas); No history of blood transfusions in the last 1 month; No history of Erythropoietin consumption
- •Exclusion criteria: Severe bleeding during the study; Hemolysis during the study due to any causes; The evidence of existing imapirment in kidney,liver,and lung function; Evidence of any serious side effects of Erythropoietin including thrombosis, increased systemic blood pressure, and polycythemia
排除标准
- 未提供
研究者
相似试验
已完成
4 期
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy.Anemia secondary to chemo and/or radiotherapy.RPCEC00000080Center of Molecular Immunology(CIM)161
尚未招募
不适用
Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgeryDiseases of the circulatory systemKCT0000696Asan Medical Center228
已完成
不适用
Recombinant human erythropoietin therapy in critically ill patients: a dose response studyCritically ill patients with anaemiaHaematological DisordersAnaemiaISRCTN48523317Janssen-Cilag (Greece)148
暂停
1 期
Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I.Acute Cerebral Ischemic Stroke.RPCEC00000078Center of Molecular Inmunology(CIM)20
已完成
不适用
Evaluation of Enteral Erythropoietin in prevention of Necrotizing Entrocolits in Very Low Birth Weight infantsecrotizing Enterocolitis of fetus and neonate.Necrotizing Enterocolitis of fetus and neonateIRCT201310164113N4Pediatric Health Research Center of Tabriz University of Medical Sceinces105